Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jul 20;63(3):240-5.
doi: 10.1016/j.maturitas.2009.03.020. Epub 2009 May 1.

The safety of 52 weeks of oral DHEA therapy for postmenopausal women

Mary Panjari  1 , Robin J Bell, Fiona Jane, Jenny Adams, Corallee Morrow, Susan R Davis
Affiliations
Randomized Controlled Trial

The safety of 52 weeks of oral DHEA therapy for postmenopausal women

Mary Panjari et al. Maturitas. .

Abstract

Objective: The aim of this study was to evaluate the safety of 52 weeks of DHEA 50mg daily oral dose given to postmenopausal women with low libido to improve sexual function.

Method: 93 postmenopausal women were enrolled in a 52-week randomised, double-blind, placebo-controlled trial and received either DHEA 50mg or placebo (PL) daily. The effects of DHEA versus placebo on lipid profile, insulin-glucose homeostasis and the endomentrium were assessed over 52 weeks.

Results: Oral DHEA, 50mg/day, was not associated with any effects on blood lipids or insulin resistance. The pattern of breakthrough bleeding did not substantially differ between the DHEA and PL groups and no significant adverse endometrial effects were apparent.

Conclusions: The use of 50mg oral DHEA did not significantly alter lipid profile, insulin sensitivity or adversely affect the endometrium in postmenopausal women.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources